Trials / Completed
CompletedNCT05582395
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 580 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavacamten | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2022-12-14
- Primary completion
- 2025-03-06
- Completion
- 2025-10-20
- First posted
- 2022-10-17
- Last updated
- 2025-11-14
Locations
224 sites across 23 countries: United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05582395. Inclusion in this directory is not an endorsement.